Literature DB >> 1001850

Plasma glucagon immunoreactivity in a totally pancreatectomized patient.

M L Villanueva, J A Hedo, J Marco.   

Abstract

Analysis of the plasma from a totally pancreatectomized patient, with antiserum 30 K, has demonstrated basal glucagon immunoreactivity (GIR) levels in the normal range (80-110 pg/ml). Neither i. v. arginine nor oral glucose affected these GIR values, thus indicating the absence of functioning pancreatic or gastrointestinal A-cells. Furthermore, filtration of whole plasma on Bio Gel P-30 showed no GIR in the 3500 MW elution volume. GIR was found to be distributed in two peaks. One peak eluted in the protein region, similarly to "big plasma glucagon" (BPG), and the second peak appeared after the glucagon-I125 marker. The protein-sized moiety was not absorbable by charcoal, and on Sephadex G-100 it eluted within the globulin region. When subjected to trypsin treatment, it yielded smaller GIR fractions. According to these criteria, it can be assumed that this component is identical to BPG. Therefore, an extrapancreatic source for BPG is suggested. On the other hand, the presence of fasting hyperglycaemia in this patient indicates that insulin deficiency by itself suffices to raise blood sugar to diabetic levels.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001850     DOI: 10.1007/bf01220639

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  High molecular weight glucagon-like immunoreactivity in plasma.

Authors:  G C Weir; S D Knowlton; D B Martin
Journal:  J Clin Endocrinol Metab       Date:  1975-02       Impact factor: 5.958

2.  Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

Authors:  I Valverde; M L Villanueva; I Lozano; J Marco
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

3.  Plasma glucose, insulin, pancreatic, and enteroglucagon levels in normal and depancreatized dogs.

Authors:  T Matsuyama; P P Foà
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

4.  Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs.

Authors:  M Vranic; S Pek; R Kawamori
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

5.  Glucagon radioimmunoassay using antiserum 30K: interference by plasma.

Authors:  G C Weir; R C Turner; D B Martin
Journal:  Horm Metab Res       Date:  1973-07       Impact factor: 2.936

6.  Characterization of the glucagon response to hypoglycemia in man.

Authors:  J E Gerich; V Schneider; S E Dippe; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1974-01       Impact factor: 5.958

7.  Large glucagon immunoreactivity in extracts of pancreas.

Authors:  D Rigopoulou; I Valverde; J Marco; G Faloona; R H Unger
Journal:  J Biol Chem       Date:  1970-02-10       Impact factor: 5.157

8.  Glucagon: role in the hyperglycemia of diabetes mellitus.

Authors:  R Dobbs; H Sakurai; H Sasaki; G Faloona; I Valverde; D Baetens; L Orci; R Unger
Journal:  Science       Date:  1975-02-14       Impact factor: 47.728

9.  Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs.

Authors:  K Mashiter; P E Harding; M Chou; G D Mashiter; J Stout; D Diamond; J B Field
Journal:  Endocrinology       Date:  1975-03       Impact factor: 4.736

10.  Pancreatectomised man: A model for diabetes without glucagon.

Authors:  A J Barnes; S R Bloom
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

View more
  16 in total

Review 1.  Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

2.  Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy.

Authors:  S Del Prato; S Vigili de Kreutzenberg; R Trevisan; E Duner; A Avogaro; R Nosadini; U Baccaglini; C Tremolada; A Tiengo
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

3.  Paradoxical elevations of plasma glucagon levels in patients after pancreatectomy or gastrectomy.

Authors:  K Ohtsuka; Y Nimura; K Yasui
Journal:  Jpn J Surg       Date:  1986-01

4.  Absence of islet alpha cell function in pancreatectomized patients.

Authors:  A Tiengo; M Bessioud; I Valverde; A Tabbi-Anneni; S Delprato; J Alexandre; R Assan
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

5.  Glucagon- and glicentin-immunoreactive cells in the human digestive tract.

Authors:  J C Garaud; R Eloy; A J Moody; C Stock; J F Grenier
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

6.  Studies on persistent circulating immunoreactive glucagon (IRG) and immunoreactive insulin (IRI) found in eviscerated rats with a functional liver.

Authors:  S S Smith; S J Bhathena; D Nompleggi; J C Penhos; L Recant
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

7.  The serum glucose response to glucagon suppression with somatostatin, insulin or antiglucagon serum in depancreatized rats.

Authors:  J C Dunbar; M F Walsh; P P Foà
Journal:  Diabetologia       Date:  1978-01-14       Impact factor: 10.122

8.  Effect of glucagon on glucose production during insulin deficiency in the dog.

Authors:  A D Cherrington; W W Lacy; J L Chiasson
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

9.  Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

Authors:  W A Muller; M Berger; P Suter; H J Cüppers; J Reiter; T Wyss; P Berchtold; F H Schmidt; J P Assal; A E Renold
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

10.  Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis.

Authors:  S Del Prato; F Riva; A Devidé; R Nosadini; D Fedele; A Tiengo
Journal:  Acta Diabetol Lat       Date:  1980 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.